Citations

Citations to this article as recorded by  

• Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases
  Niloofar Khoshnam-Rad, Homayoon Vahedi, Anahita Sadeghi, Mansoor Rastegarpanah, Soha Namazi, Amir Anushiravani, Ali Reza Sima, Shabnam Shahrokh, Sudabeh Alatab, Reza Malekzadeh
  Middle East Journal of Digestive Diseases.2023; 15(2): 83.     CrossRef
• Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review
  Elham Zarenezhad, Hussein T. Abdulabbas, Ahmed Shayaa Kareem, Seyed Amin Kouhpayeh, Silvia Barbaresi, Sohrab Najafipour, Abdulbaset Mazarzaei, Mitra Sotoudeh, Abdolmajid Ghasemian
  Archives of Microbiology.2023;[Epub]     CrossRef
• The impact of medication belief on adherence to infliximab in patients with Crohn’s disease
  Shuyan Li, Yan Ma, Hongling Sun, Zijun Ni, Shurong Hu, Yan Chen, Meijuan Lan
  Frontiers in Pharmacology.2023;[Epub]     CrossRef
• SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID
  Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
  Intestinal Research.2022; 20(2): 171.     CrossRef
• Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
  Ji Min Lee, Shu-Chen Wei, Kang-Moon Lee, Byong Duk Ye, Ren Mao, Hyun-Soo Kim, Soo Jung Park, Sang Hyoung Park, Eun Hye Oh, Jong Pil Im, Byung Ik Jang, Dae Bum Kim, Ken Takeuchi
  Gut and Liver.2022; 16(3): 396.     CrossRef
• Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
  Eun Ae Kang, Jae Hee Cheon
  Gut and Liver.2022; 16(4): 501.     CrossRef
• Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
  Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong
  Gut and Liver.2022; 16(4): 567.     CrossRef
• Inflammatory bowel disease in Korea: epidemiology and pathophysiology
  Jung Won Lee, Chang Soo Eun
  The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
• Viral Hepatitis in Patients with Inflammatory Bowel Disease
  Seung Hwan Shin, Sang Hyoung Park
  The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
• Vaccination strategies for Korean patients with inflammatory bowel disease
  Yoo Jin Lee, Eun Soo Kim
  The Korean Journal of Internal Medicine.2022; 37(5): 920.     CrossRef
• Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study
  Hong Yang, Zhihua Ran, Meng Jin, Jia-Ming Qian
  Gut and Liver.2022; 16(5): 726.     CrossRef
• Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease?
  Suhyun Park, Sang Hyoung Park
  Gut and Liver.2022; 16(5): 663.     CrossRef
• Natural history of inflammatory bowel disease: a comparison between the East and the West
  Eun Mi Song, Suk-Kyun Yang
  Intestinal Research.2022; 20(4): 418.     CrossRef
• Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases: The Current Approach
  Vlad Alexandru Ionescu, Gina Gheorghe, Valentin Nicolae Varlas, Ana Maria Alexandra Stanescu, Camelia Cristina Diaconu
  Gastroenterology Insights.2022; 14(1): 13.     CrossRef
• Viral infections in inflammatory bowel disease: Tips and tricks for correct management
  Vincenzo Craviotto, Federica Furfaro, Laura Loy, Alessandra Zilli, Laurent Peyrin-Biroulet, Gionata Fiorino, Silvio Danese, Mariangela Allocca
  World Journal of Gastroenterology.2021; 27(27): 4276.     CrossRef
• SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID
  Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung
  The Korean Journal of Gastroenterology.2021; 78(2): 117.     CrossRef
• Current status of inflammatory bowel diseases in Korea
  Suk-Kyun Yang
  Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
• A clinical case of ulcerative colitis in a patient with viral hepatitis
  E. D. Kosmachova, M. S. Iakovenko, K. A. Yumukian
  South Russian Journal of Therapeutic Practice.2020; 1(3): 95.     CrossRef

Citations

Citations to this article as recorded by  

• Anxiety and Depression Are Associated with Poor Long-term Quality of Life in Moderate-to-Severe Ulcerative Colitis: Results of a 3-Year Longitudinal Study of the MOSAIK Cohort
  Shin Ju Oh, Chang Hwan Choi, Sung-Ae Jung, Geun Am Song, Yoon Jae Kim, Ja Seol Koo, Sung Jae Shin, Geom Seog Seo, Kang-Moon Lee, Byung Ik Jang, Eun Suk Jung, Youngdoe Kim, Chang Kyun Lee
  Gut and Liver.2025; 19(2): 253.     CrossRef
• Effectiveness of Early Thiopurine Use in Korean Patients With Moderate-to-Severe Ulcerative Colitis
  Hye Kyung Hyun, Ji Won Kim, Jun Lee, Yoon Tae Jeen, Tae-Oh Kim, Joo Sung Kim, Jae Jun Park, SungNoh Hong, Dong Il Park, Hyun-Soo Kim, YooJin Lee, Eun Suk Jung, Youngdoe Kim, Su Young Jung, Jae Hee Cheon
  Journal of Clinical Gastroenterology.2024;[Epub]     CrossRef
• Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea
  Hyuk Yoon, Young Soo Park, Jeong Eun Shin, Byong Duk Ye, Chang Soo Eun, Soon Man Yoon, Jae Myung Cha, You Sun Kim, Kyu Chan Huh, Young Sook Park, Jae Hee Cheon, Eun Suk Jung, Youngdoe Kim, Su Young Jung
  BMC Gastroenterology.2023;[Epub]     CrossRef
• Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
  Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
  Gut and Liver.2022; 16(1): 138.     CrossRef
• Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year
  Ik Hyun Jo, Kang-Moon Lee, Dae Bum Kim, Ji Won Kim, Jun Lee, Yoon Tae Jeen, Tae-Oh Kim, Joo Sung Kim, Jae Jun Park, Sung Noh Hong, Dong Il Park, Hyun-Soo Kim, Yoo Jin Lee, Youngdoe Kim
  Gut and Liver.2022; 16(3): 384.     CrossRef
• Ulcerative Colitis and Patient’s Quality of Life, Especially in Early Stage
  Jung Won Lee
  Gut and Liver.2022; 16(3): 317.     CrossRef
• Early course of newly diagnosed moderate‐to‐severe ulcerative colitis in Korea: Results from a hospital‐based inception cohort study (MOSAIK)
  Jin Young Yoon, Jae Myung Cha, Chang Kyun Lee, Young Sook Park, Kyu Chan Huh, Jeong Eun Shin, You Sun Kim, Chang Soo Eun, Soon Man Yoon, Jae Hee Cheon, Young Soo Park, Byong Duk Ye, YoungJa Lee, Youngdoe Kim, Hyo Jong Kim
  Journal of Gastroenterology and Hepatology.2021; 36(8): 2149.     CrossRef
• Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study
  Ju-Young Shin, Hye-Min Park, Min-Young Lee, Ja-Young Jeon, Hyun-Jeong Yoo, Byong Duk Ye
  Gut and Liver.2021; 15(6): 867.     CrossRef
• Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
  Suk-Kyun Yang, Sang Hyoung Park, Byong Duk Ye
  Gut and Liver.2021; 15(6): 942.     CrossRef
• Anxiety and Depression in Patients with Inflammatory Bowel Diseases: The First Step toward Proper Management
  Jung Won Lee
  Gut and Liver.2020; 14(4): 395.     CrossRef
• Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
  Jung Rock Moon, Chang Kyun Lee, Sung Noh Hong, Jong Pil Im, Byong Duk Ye, Jae Myung Cha, Sung-Ae Jung, Kang-Moon Lee, Dong Il Park, Yoon Tae Jeen, Young Sook Park, Jae Hee Cheon, Hyesung Kim, BoJeong Seo, Youngdoe Kim, Hyo Jong Kim
  Gut and Liver.2020; 14(4): 459.     CrossRef
• Quantitative Proteomic Analysis of the Expression of SARS-CoV-2 Receptors in the Gut of Patients with Chronic Enterocolitis
  Jihye Park, Daeun Jeong, Youn Wook Chung, Da Hye Kim, Jae Hee Cheon, Ji-Hwan Ryu
  Yonsei Medical Journal.2020; 61(10): 891.     CrossRef

Citations

Citations to this article as recorded by  

• Inflammatory bowel disease in Korea: epidemiology and pathophysiology
  Jung Won Lee, Chang Soo Eun
  The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised 3 parts: management of latent TB in preparation for anti-TNF therapy, monitoring during anti-TNF therapy, and management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Citations

Citations to this article as recorded by  

• Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study
  Rongbei Liu, Zhilun Li, Lingna Ye, Jing Hu, Jian Tang, Baili Chen, Xiuli Chen, Bei Tan, Yubei Gu, Chen Xie, Chunhui Ouyang, Xiaomei Song, Fan Li, Yanyun Fan, Haixia Ren, Liangru Zhu, Min Chen, Wenyu Jiang, Qian Cao
  Inflammatory Bowel Diseases.2024; 30(1): 45.     CrossRef
• Reduced gut microbiota diversity in ulcerative colitis patients with latent tuberculosis infection during vedolizumab therapy: insights on prophylactic anti-tuberculosis effects
  Yibing Hu, Zhenping Wu, Xiaoyun Yang, Jin Ding, Qunying Wang, Hao Fang, Lujian Zhu, Minli Hu
  BMC Microbiology.2024;[Epub]     CrossRef
• Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
  Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
  Journal of Gastroenterology and Hepatology.2023; 38(4): 523.     CrossRef
• Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
  Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
  Intestinal Research.2023; 21(1): 61.     CrossRef
• Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
  Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
  ACG Case Reports Journal.2023; 10(6): e01066.     CrossRef
• IBD barriers across the continents – East Asia
  Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
  Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
• Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
  Jae Hoon Jung, Sujin Choi, Youra Kang, Dae-Chul Cho, So Mi Lee, Tae In Park, Byung-Ho Choe, Dongsub Kim, Ben Kang
  Frontiers in Pediatrics.2022;[Epub]     CrossRef
• A case of paradoxical response during anti-tuberculosis treatment in a patient with ulcerative colitis
  Shuhei Hosomi, Naoko Sugita, Atsushi Kanamori, Masaki Ominami, Koji Otani, Noriko Kamata, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Yasuhiro Fujiwara
  Clinical Journal of Gastroenterology.2022; 15(3): 592.     CrossRef
• Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study
  Fen Liu, Jian Tang, Lingna Ye, Jinyu Tan, Yun Qiu, Fan Hu, Jinshen He, Baili Chen, Yao He, Zhirong Zeng, Ren Mao, Qian Cao, Xiang Gao, Minhu Chen
  Clinical and Translational Gastroenterology.2022; 13(6): e00493.     CrossRef
• Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
  Sujin Choi, Bong Seok Choi, Byung-Ho Choe, Ben Kang
  Yeungnam University Journal of Medicine.2021; 38(3): 251.     CrossRef
• Current status of inflammatory bowel diseases in Korea
  Suk-Kyun Yang
  Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
• Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
  Yunho Jung
  The Korean Journal of Gastroenterology.2020; 75(1): 1.     CrossRef
• Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
  Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
  The Korean Journal of Gastroenterology.2020; 75(1): 29.     CrossRef
• Preoperative hypoalbuminemia is an independent risk factor for postoperative complications in Crohn's disease patients with normal BMI: A cohort study
  Xiaolong Ge, Huaying Liu, Shasha Tang, Yan Wu, Yipeng Pan, Wei Liu, Weilin Qi, Lingna Ye, Qian Cao, Wei Zhou
  International Journal of Surgery.2020; 79: 294.     CrossRef
• Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
  Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul
  Gut and Liver.2020; 14(6): 685.     CrossRef
• Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
  Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
  International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
• Translating the gut microbiome: ready for the clinic?
  Susan V. Lynch, Siew C. Ng, Fergus Shanahan, Herbert Tilg
  Nature Reviews Gastroenterology & Hepatology.2019; 16(11): 656.     CrossRef
• Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
  Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
  The Korean Journal of Gastroenterology.2019; 74(3): 168.     CrossRef
• Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)
  
  Intestinal Research.2018; 16(2): 178.     CrossRef
• A rare case of disseminated histoplasmosis in a patient with Crohn’s disease on immunosuppressive treatment
  Bhavesh Bhut, Akshay Kulkarni, Varnika Rai, Vinita Agrawal, Abhai Verma, Manoj Jain, Rungmei S K Marak, Ajai Kumar Dixit, Uday C Ghoshal
  Indian Journal of Gastroenterology.2018; 37(5): 472.     CrossRef
• High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
  Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
  Intestinal Research.2018; 16(4): 588.     CrossRef

Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from 9 Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 1 of the statements comprised 2 parts: risk of TB infection Recommendaduring anti-TNF therapy, and screening for TB infection prior to commencing anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.

Citations

Citations to this article as recorded by  

• Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study
  Rongbei Liu, Zhilun Li, Lingna Ye, Jing Hu, Jian Tang, Baili Chen, Xiuli Chen, Bei Tan, Yubei Gu, Chen Xie, Chunhui Ouyang, Xiaomei Song, Fan Li, Yanyun Fan, Haixia Ren, Liangru Zhu, Min Chen, Wenyu Jiang, Qian Cao
  Inflammatory Bowel Diseases.2024; 30(1): 45.     CrossRef
• (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review
  Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange
  Clinical Microbiology and Infection.2024; 30(8): 989.     CrossRef
• Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease
  Vineet Ahuja, Ida Hilmi, Byong Duk Ye, Khoon Lin Ling, Siew C. Ng, Rupert W. Leong, Peeyush Kumar, Xin Hui Khoo, Govind K. Makharia, Jose Sollano, Pises Pisespongsa, Nazri Mustaffa, Rupa Banerjee, Alex Hwong‐Ruey Leow, Raja Affendi Raja Ali, Sai Wei Chuah
  Journal of Gastroenterology and Hepatology.2024; 39(8): 1500.     CrossRef
• Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
  Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
  Intestinal Research.2023; 21(1): 61.     CrossRef
• Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients
  Flora Maria Lorenzo Fortes, Raquel Rocha, Genoile Oliveira Santana
  World Journal of Gastroenterology.2023; 29(9): 1536.     CrossRef
• Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
  Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
  Clinical Endoscopy.2023; 56(2): 239.     CrossRef
• Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib
  Shruti Verma, Arshdeep Singh, Chandan Kakkar, Ashish Tripathi, Vandana Midha, Ajit Sood
  ACG Case Reports Journal.2023; 10(6): e01066.     CrossRef
• Intestinal tuberculosis can masquerade as Crohn’s disease: A teachable moment
  Pooja KC, Madhur Bhattarai, Subodh Adhikari, Prakriti Parajuli, Sujata Bhandari, Himal Bikram Bhattarai, Niraj Kumar Sharma, Shailendra Karki, Suryakiran Acharya, Bibhusan Basnet
  SAGE Open Medical Case Reports.2023;[Epub]     CrossRef
• The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report
  Yuya Sugiyama, Nobuhiro Ueno, Shion Tachibana, Yu Kobayashi, Yuki Murakami, Takahiro Sasaki, Aki Sakatani, Keitaro Takahashi, Katsuyoshi Ando, Shin Kashima, Kentaro Moriichi, Hiroki Tanabe, Toshikatsu Okumura, Mikihiro Fujiya
  Medicine.2023; 102(28): e34331.     CrossRef
• Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis
  Sayan Malakar, Srikanth Kothalkar, Umair Shamsul Hoda, Uday C Ghoshal
  Cureus.2023;[Epub]     CrossRef
• Crohn’s disease and intestinal tuberculosis: challenging from every angle
  Andreia Guimarães, João Gama, Luis Curvo-Semedo, António Canaveira Manso
  BMJ Case Reports.2023; 16(12): e254400.     CrossRef
• Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review
  Jae Hoon Jung, Sujin Choi, Youra Kang, Dae-Chul Cho, So Mi Lee, Tae In Park, Byung-Ho Choe, Dongsub Kim, Ben Kang
  Frontiers in Pediatrics.2022;[Epub]     CrossRef
• Increased Risk of Infection With High Infliximab Trough Level
  Suprabhat Giri, Harish Darak
  Journal of Clinical Gastroenterology.2022; 56(4): 374.     CrossRef
• Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
  Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung
  Journal of Personalized Medicine.2022; 12(3): 507.     CrossRef
• Evidence-Based Commentary: Testing and Treating Latent Tuberculosis Before Starting Biologics and Small Molecules in Patients with Inflammatory Bowel Disease
  Rinkalben Kakadiya, Vishal Sharma
  Journal of Gastrointestinal Infections.2022; 12(02): 128.     CrossRef
• Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors
  Kyuwon Kim, Kyung-Wook Jo, Tae Sun Shim, Jin Hwa Park, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
  Frontiers in Medicine.2021;[Epub]     CrossRef
• Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
  Sujin Choi, Bong Seok Choi, Byung-Ho Choe, Ben Kang
  Yeungnam University Journal of Medicine.2021; 38(3): 251.     CrossRef
• Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
  Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
  Intestinal Research.2021; 19(4): 419.     CrossRef
• Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region
  Lingna Ye, Thomas P. Chapman, Zhenzhen Wen, Lang Lin, Yun Qiu, Zhanju Liu, Zhihua Ran, Jiaming Qian, Kaichun Wu, Xiang Gao, Pinjin Hu, Minhu Chen, Simon P. L. Travis, Qian Cao
  Alimentary Pharmacology & Therapeutics.2021; 53(3): 390.     CrossRef
• Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
  Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, Shashi Adsul
  Gut and Liver.2020; 14(6): 685.     CrossRef
• Increased Risk of Herpes Zoster in Young and Metabolically Healthy Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
  Hosim Soh, Jaeyoung Chun, Kyungdo Han, Seona Park, Gukhwan Choi, Jihye Kim, Jooyoung Lee, Jong Pil Im, Joo Sung Kim
  Gut and Liver.2019; 13(3): 333.     CrossRef
• Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center
  Mafalda Sousa, Inês Ladeira, Ana Ponte, Carlos Fernandes, Adélia Rodrigues, Ana P. Silva, João Silva, Catarina Gomes, Edgar Afeto, João Carvalho
  European Journal of Gastroenterology & Hepatology.2019; 31(9): 1099.     CrossRef
• The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
  Joyce WY Mak, Joseph JY Sung
  Journal of Gastroenterology and Hepatology.2019; 34(8): 1269.     CrossRef
• Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease
  Youn I Choi, Tae Jun Kim, Dong Kyun Park, Jun-won Chung, Kyoung Oh Kim, Kwang An Kwon, Yoon Jae Kim
  International Journal of Colorectal Disease.2019; 34(10): 1713.     CrossRef
• Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
  Yu Kyung Jun, Jaeyoung Chun, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im, Joo Sung Kim
  The Korean Journal of Gastroenterology.2019; 74(3): 168.     CrossRef
• Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)
  
  Intestinal Research.2018; 16(2): 178.     CrossRef
• High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
  Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja
  Intestinal Research.2018; 16(4): 588.     CrossRef
• Risk of infection associated with anti-TNF-α therapy
  Mario Fernández-Ruiz, José María Aguado
  Expert Review of Anti-infective Therapy.2018; 16(12): 939.     CrossRef

Colonoscopy is currently regarded as the gold standard and preferred method of screening for colorectal cancer (CRC). However, the benefit of colonoscopy screening may be blunted by low participation rates in population-based screening programs. Harmful effects of population-based colonoscopy screening may include complications induced by colonoscopy itself and by sedation, psychosocial distress, potential over-diagnosis, and socioeconomic burden. In addition, harmful effects of colonoscopy may increase with age and comorbidities. As the risk of adverse events in population-based colonoscopy screening may offset the benefit, the adverse events should be managed and monitored. To adopt population-based colonoscopy screening, consensus on the risks and benefits should be developed, focusing on potential harm, patient preference, socioeconomic considerations, and quality improvement of colonoscopy, as well as efficacy for CRC prevention. As suboptimal colonoscopy quality is a major pitfall of population-based screening, adequate training and regulation of screening colonoscopists should be the first step in minimizing variations in quality. Gastroenterologists should promote quality improvement, auditing, and training for colonoscopy in a population-based screening program.

Citations

Citations to this article as recorded by  

• Glycoproteomics of Gastrointestinal Cancers and Its Use in Clinical Diagnostics
  Tomas Bertok, Andrea Pinkeova, Lenka Lorencova, Anna Datkova, Michal Hires, Eduard Jane, Jan Tkac
  Journal of Proteome Research.2025; 24(6): 2584.     CrossRef
• Evaluation of the “Burgenland PREvention trial of colorectal cancer Disease with ImmunologiCal Testing” (B-PREDICT)—a population-based colorectal cancer screening program
  Stefanie BREZINA, Gernot LEEB, Andreas BAIERL, Evelyn GRÄF, Monika HACKL, Philipp HOFER, Harald LANG, Michaela KLEIN, Karl MACH, Remy SCHWARZER, Wilhelm WLASSITS, Andreas PÜSPÖK, Andrea GSUR
  BMC Gastroenterology.2024;[Epub]     CrossRef
• Strategies to improve screening colonoscopy quality for the prevention of colorectal cancer
  Joo Hye Song, Eun Ran Kim
  The Korean Journal of Internal Medicine.2024; 39(4): 547.     CrossRef
• The adult large bowel: describing environment morphology for effective biomedical device development
  Joseph C Norton, James W Martin, Conchubhair Winters, Bruno Scaglioni, Keith L Obstein, Venkataraman Subramanian, Pietro Valdastri
  Progress in Biomedical Engineering.2024; 6(3): 032003.     CrossRef
• Efficacy of colonoscopic re-examination across the entire colon: a randomized controlled trial
  Dong Seok Lee, Jeong-Seon Ji, Tae-Geun Gweon, Myeongsook Seo, Hwang Choi
  Surgical Endoscopy.2024; 38(11): 6711.     CrossRef
• Comment on " Positive fecal immunochemical test results are associated with non-colorectal cancer mortality"
  Yong Eun Park
  The Korean Journal of Internal Medicine.2023; 38(2): 264.     CrossRef
• Challenges and Suggestions in the Management of Stomach and Colorectal Cancer in Uzbekistan: The Third Report of the Uzbekistan–Korea Oncology Consortium
  Chai Hong Rim, Won Jae Lee, Odiljon Akhmedov, Ulugbek Sabirov, Yakov Ten, Yakhyo Ziyayev, Mirzagaleb Tillyashaykhov, Jae Suk Rim
  International Journal of Environmental Research and Public Health.2023; 20(8): 5477.     CrossRef
• Gastrointestinal Cancer Prevention Policies
  Neda Kabiri, Rahim Khodayari-zarnaq, Manouchehr Khoshbaten, Ali Janati
  International Journal of Preventive Medicine.2022; 13(1): 8.     CrossRef
• Quality indicators in colonoscopy: the chasm between ideal and reality
  Su Bee Park, Jae Myung Cha
  Clinical Endoscopy.2022; 55(3): 332.     CrossRef
• Effect of prophylactic clip application for the prevention of postpolypectomy bleeding of large pedunculated colonic polyps: a randomized controlled trial
  Tae-Geun Gweon, Kang-Moon Lee, Seung-Woo Lee, Dae Bum Kim, Jeong-Seon Ji, Ji Min Lee, Woo Chul Chung, Chang-Nyol Paik, Hwang Choi
  Gastrointestinal Endoscopy.2021; 94(1): 148.     CrossRef
• Comparison of adenoma detection by colonoscopy between polypectomy performed during both insertion and withdrawal versus during withdrawal only: a multicenter, randomized, controlled trial
  Tae-Geun Gweon, Seung-Woo Lee, Jeong-Seon Ji, Jeong Rok Lee, Joon Sung Kim, Byung-Wook Kim, Hwang Choi
  Surgical Endoscopy.2020; 34(12): 5461.     CrossRef
• Strategies to Increase the Participation Rate of Colorectal Cancer Screening
  Yoon Suk Jung
  Gut and Liver.2020; 14(3): 277.     CrossRef
• UEG Week 2018 Poster Presentations
  
  United European Gastroenterology Journal.2018;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Cronkhite-Canada Syndrome Associated with Serrated Adenoma and Malignant Polyp: A Case Report and a Literature Review of 13 Cronkhite-Canada Syndrome Cases in Korea
  So Hee Yun, Jin Woong Cho, Ji Woong Kim, Joong Keun Kim, Moon Sik Park, Na Eun Lee, Jae Un Lee, Young Jae Lee
  Clinical Endoscopy.2013; 46(3): 301.     CrossRef
• A Case of Cronkhite-Canada Syndrome Showing Spontaneous Remission
  Dong-Uk Kang, Dong-Hoon Yang, Yunsik Choi, Ji-Beom Kim, Ho-Su Lee, Hyo Jeong Lee, Sang Hyoung Park, Kee Wook Jung, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jin-Ho Kim
  Intestinal Research.2013; 11(4): 317.     CrossRef

Citations

Citations to this article as recorded by  

• The optimal bowel preparation intervals before colonoscopy: A randomized study comparing polyethylene glycol and low-volume solutions
  Vladimir Kojecky, Jan Matous, Radan Keil, Milan Dastych, Zdena Zadorova, Michal Varga, Radek Kroupa, Jiri Dolina, Miroslav Misurec, Ales Hep, Martin Griva
  Digestive and Liver Disease.2018; 50(3): 271.     CrossRef
• Comparative Study on Bowel Preparation Efficacy of Ascorbic Acid Containing Polyethylene Glycol by Adding Either Simethicone or 1 L of Water in Health Medical Examination Patients: A Prospective Randomized Controlled Study
  Se Hwan Yeo, Jae Hoon Kwak, Yeo Un Kim, Tae Ho Kwon, Jeong Bae Park, Jun Hyung Park, Yong Kook Lee, Yun Jeong Lim, Chang Heon Yang
  The Korean Journal of Gastroenterology.2016; 67(4): 189.     CrossRef
• Randomized Controlled Trial of Sodium Phosphate Tablets versus 2 L Polyethylene Glycol Solution for Bowel Cleansing prior to Colonoscopy
  Yun Ho Lee, Seong Yeon Jeong, You Sun Kim, Hye Jin Jung, Min Jung Kwon, Cheol Hun Kwak, Song I Bae, Jeong Seop Moon, Ji Won Kim, Su Hwan Kim, Kook Lae Lee
  The Korean Journal of Gastroenterology.2015; 65(1): 27.     CrossRef
• Importance of the Time Interval between Bowel Preparation and Colonoscopy in Determining the Quality of Bowel Preparation for Full-Dose Polyethylene Glycol Preparation
  Tae Kyung Kim, Hyung Wook Kim, Su Jin Kim, Jong Kun Ha, Hyung Ha Jang, Young Mi Hong, Su Bum Park, Cheol Woong Choi, Dae Hwan Kang
  Gut and Liver.2014; 8(6): 625.     CrossRef
• A Comparison of 2 L of Polyethylene Glycol and 45 mL of Sodium Phosphate versus 4 L of Polyethylene Glycol for Bowel Cleansing: A Prospective Randomized Trial
  Suh Eun Bae, Kyung-Jo Kim, Jun Bum Eum, Dong Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jin-Ho Kim
  Gut and Liver.2013; 7(4): 423.     CrossRef
• A Clear Liquid Diet Is Not Mandatory for Polyethylene Glycol-Based Bowel Preparation for Afternoon Colonoscopy in Healthy Outpatients
  Yoon Suk Jung, Hyo Sun Seok, Dong Il Park, Chang Seok Song, Seong Eun Kim, Suck Ho Lee, Chang Soo Eun, Dong Soo Han, Yong Soo Kim, Chang Kyun Lee
  Gut and Liver.2013; 7(6): 681.     CrossRef
• Comparison of Bowel Preparation Quality between Clear-liquid Diet and No Diet Restriction
  Woo Shin Jeong, Dong Il Park, Hyo Sun Seok, Seong Eun Kim, Suck-Ho Lee, Chang Kyun Lee, Chang Soo Eun, Dong Soo Han
  Intestinal Research.2012; 10(3): 272.     CrossRef
• Comparison among Conventional 4 L Polyethylene Glycol, Split Method of 4 L Polyethylene Glycol and Combination of 2 L Polyethylene Glycol and Sodium Phosphate Solution for Colonoscopy Preparation
  So Young Jo, Nayoung Kim, Jung Won Lee, Ji Hwan Lim, Chiun Choi, Ilyoung Chon, Ho Kil, Bo Young Min, Young Sang Byoun, Ban Seok Lee, Sang Eon Jang, Hyun Kyung Park, Hyun Jin Jo, Cheol Min Shin, Sang Hyup Lee, Young Soo Park, Jin-Hyeok Hwang, Jin-Wook Kim,
  The Korean Journal of Gastroenterology.2012; 59(6): 414.     CrossRef